237 related articles for article (PubMed ID: 31896113)
1. Immunohistochemical Analysis of mTOR Pathway-Related Proteins in Kaposiform Hemangioendothelioma.
Wang Z; Zheng C; Sun H; Yao W; Li K; Ma Y; Zheng S
Dermatology; 2020; 236(3):262-270. PubMed ID: 31896113
[TBL] [Abstract][Full Text] [Related]
2. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin induces autophagy and apoptosis in Kaposiform hemangioendothelioma primary cells in vitro.
Wang Z; Han Q; Wang J; Yao W; Wang L; Li K
J Pediatr Surg; 2022 Jul; 57(7):1274-1280. PubMed ID: 35428493
[TBL] [Abstract][Full Text] [Related]
4. Overexpression Prox1 in HemECs resembles Kaposiform hemangioendothelioma and cytotoxicity of sirolimus in vitro.
Wang J; Han Q; Yan H; Yao W; Wang Z; Li K
J Pediatr Surg; 2021 Jul; 56(7):1203-1210. PubMed ID: 33865602
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
[TBL] [Abstract][Full Text] [Related]
7. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
Wang H; Guo X; Duan Y; Zheng B; Gao Y
Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus ointment for the treatment of superficial kaposiform hemangioendothelioma and tufted angioma.
Zhang X; Yang K; Chen S; Ji Y
J Dermatol; 2019 Oct; 46(10):898-901. PubMed ID: 31373046
[TBL] [Abstract][Full Text] [Related]
10. Ultrasonography and magnetic resonance imaging features of kaposiform hemangioendothelioma and tufted angioma.
Gong X; Ying H; Zhang Z; Wang L; Li J; Ding A; Zhou L; Lin X; Xiong P
J Dermatol; 2019 Oct; 46(10):835-842. PubMed ID: 31373042
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
12. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
13. Analysis of mTOR pathway expression in lymphatic malformation and related diseases.
Hori Y; Ozeki M; Hirose K; Matsuoka K; Matsui T; Kohara M; Tahara S; Toyosawa S; Fukao T; Morii E
Pathol Int; 2020 Jun; 70(6):323-329. PubMed ID: 32067331
[TBL] [Abstract][Full Text] [Related]
14. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Chiu YE; Drolet BA; Blei F; Carcao M; Fangusaro J; Kelly ME; Krol A; Lofgren S; Mancini AJ; Metry DW; Recht M; Silverman RA; Tom WL; Pope E
Pediatr Blood Cancer; 2012 Nov; 59(5):934-8. PubMed ID: 22648868
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.
Kai L; Wang Z; Yao W; Dong K; Xiao X
J Cancer Res Clin Oncol; 2014 Mar; 140(3):471-6. PubMed ID: 24464150
[TBL] [Abstract][Full Text] [Related]
16. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.
Oza VS; Mamlouk MD; Hess CP; Mathes EF; Frieden IJ
Pediatr Dermatol; 2016; 33(2):e88-92. PubMed ID: 26864138
[TBL] [Abstract][Full Text] [Related]
17. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
18. Kaposiform hemangioendothelioma: current knowledge and future perspectives.
Ji Y; Chen S; Yang K; Xia C; Li L
Orphanet J Rare Dis; 2020 Feb; 15(1):39. PubMed ID: 32014025
[TBL] [Abstract][Full Text] [Related]
19. The use of mTOR inhibitors for the treatment of kaposiform hemangioendothelioma. A systematic review.
Maza-Morales M; Valdés-Loperena S; Durán-McKinster LC; García-Romero MT
Pediatr Dermatol; 2023; 40(3):440-445. PubMed ID: 36716766
[TBL] [Abstract][Full Text] [Related]
20. Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.
Boscolo E; Pastura P; Glaser K; Goines J; Hammill AM; Adams DM; Dickie P; Hsi Dickie B; Le Cras TD
Pediatr Blood Cancer; 2019 Aug; 66(8):e27790. PubMed ID: 31045327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
